Multipotent MAO and cholinesterase inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amine.

[1]  V. Andrisano,et al.  Synthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analogues. , 2011, European journal of medicinal chemistry.

[2]  V. Andrisano,et al.  Chemical and Pharmacological Studies on Enantiomerically Pure p‐Methoxytacripyrines, Promising Multi‐Target‐Directed Ligands for the Treatment of Alzheimer’s Disease , 2011, ChemMedChem.

[3]  D. Edmondson,et al.  ²H kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: comparisons with the human enzyme. , 2011, Biochemistry.

[4]  Irene Bolea,et al.  Synthesis, biological assessment and molecular modeling of new multipotent MAO and cholinesterase inhibitors as potential drugs for the treatment of Alzheimer's disease. , 2011, European journal of medicinal chemistry.

[5]  A. Leo,et al.  Erratum: Multi‐pH QSAR: A Method to Differentiate the Activity of Neutral and Ionized Species and Obtain True Correlations when Both Species are Involved , 2010, Molecular informatics.

[6]  D. Secci,et al.  Synthesis of new 3-aryl-4,5-dihydropyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. , 2010, European journal of medicinal chemistry.

[7]  Manuela G. López,et al.  Multipotent drugs with cholinergic and neuroprotective properties for the treatment of Alzheimer and neuronal vascular diseases. I. Synthesis, biological assessment, and molecular modeling of simple and readily available 2-aminopyridine-, and 2-chloropyridine-3,5-dicarbonitriles. , 2010, Bioorganic & medicinal chemistry.

[8]  R. León,et al.  Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. , 2010, Journal of medicinal chemistry.

[9]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[10]  M. Youdim,et al.  Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy. , 2009, Journal of medicinal chemistry.

[11]  Abdelouahid Samadi,et al.  Recent advances in the Friedländer reaction. , 2009, Chemical reviews.

[12]  Caroline Papin,et al.  Fast access to robust C-sialoside multimers. , 2009, Chemistry.

[13]  N. Durany,et al.  Oxidative stress in Alzheimer disease , 2009, Cell adhesion & migration.

[14]  Torsten Schwede,et al.  The SWISS-MODEL Repository and associated resources , 2008, Nucleic Acids Res..

[15]  E. Yamashita,et al.  Structure of human monoamine oxidase A at 2.2-Å resolution: The control of opening the entry for substrates/inhibitors , 2008, Proceedings of the National Academy of Sciences.

[16]  Maurizio Recanatini,et al.  Multi-target-directed ligands to combat neurodegenerative diseases. , 2008, Journal of medicinal chemistry.

[17]  A. Cavalli,et al.  Insight Into the Kinetic of Amyloid β (1–42) Peptide Self‐Aggregation: Elucidation of Inhibitors’ Mechanism of Action , 2007, Chembiochem : a European journal of chemical biology.

[18]  R. Ramsay,et al.  Variations in activity and inhibition with pH: the protonated amine is the substrate for monoamine oxidase, but uncharged inhibitors bind better , 2007, Journal of Neural Transmission.

[19]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[20]  Ana Martínez,et al.  Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. , 2006, Current pharmaceutical design.

[21]  M. Youdim,et al.  Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil , 2006, Neurotoxicity Research.

[22]  P. Camps,et al.  Dimeric and hybrid anti-Alzheimer drug candidates. , 2006, Current medicinal chemistry.

[23]  Torsten Schwede,et al.  The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling , 2006, Bioinform..

[24]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[25]  A. Mattevi,et al.  Structure and mechanism of monoamine oxidase. , 2004, Current medicinal chemistry.

[26]  H. Feldman,et al.  Treatment of Alzheimer's disease; current status and new perspectives , 2003, The Lancet Neurology.

[27]  E. Giacobini,et al.  Cholinergic function and Alzheimer's disease , 2003, International journal of geriatric psychiatry.

[28]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[29]  Wei Huang,et al.  Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. , 2002, Journal of medicinal chemistry.

[30]  A. Morreale,et al.  Ligand-receptor interaction at the neural nicotinic acetylcholine binding site: a theoretical model. , 2002, Journal of molecular graphics & modelling.

[31]  V. Talesa.  Acetylcholinesterase in Alzheimer's disease , 2001, Mechanisms of Ageing and Development.

[32]  P. Carrupt,et al.  Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. , 2001, Journal of medicinal chemistry.

[33]  N. Cutler,et al.  Review of the acetylcholinesterase inhibitor galanthamine , 2000, Expert opinion on investigational drugs.

[34]  M. Unzeta,et al.  Relevance of benzyloxy group in 2‐indolyl methylamines in the selective MAO‐B inhibition , 1999, British journal of pharmacology.

[35]  C. Spencer,et al.  Rivastigmine. A review of its use in Alzheimer's disease. , 1998, Drugs & aging.

[36]  S. Gray,et al.  Donepezil Use in Alzheimer Disease , 1998, The Annals of pharmacotherapy.

[37]  G. O'malley,et al.  Imino 1,2,3,4-tetrahydrocyclopent[b]indole carbamates as dual inhibitors of acetylcholinesterase and monoamine oxidase , 1996 .

[38]  Manuel C. Peitsch,et al.  Protein Modeling by E-mail , 1995, Bio/Technology.

[39]  H. Levine,et al.  Thioflavine T interaction with synthetic Alzheimer's disease β‐amyloid peptides: Detection of amyloid aggregation in solution , 1993, Protein science : a publication of the Protein Society.

[40]  A. Boulton,et al.  Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. , 1992, Journal of medicinal chemistry.

[41]  K. Higuchi,et al.  Kinetic analysis of amyloid fibril polymerization in vitro. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[42]  F. Mȕller.  Chemistry and Biochemistry of Flavoenzymes: Volume I , 1991 .

[43]  J. Montgomery,et al.  Syntheses and antifolate activity of 5-methyl-5-deaza analogues of aminopterin, methotrexate, folic acid, and N10-methylfolic acid. , 1986, Journal of medicinal chemistry.

[44]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[45]  M. Mittelbach,et al.  SYNTHESES WITH NITRILES. 62. 3,5‐DICYANOPYRIDINE DERIVATIVES BY VILSMEIER FORMYLATION OF MALONONITRILE AND TETRACYANOPROPENIDES , 1982 .

[46]  K. Tipton,et al.  Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. , 1981, Biochemical pharmacology.

[47]  H. Junek,et al.  Zur Synthese von Alkoxymethylenmalonitrilen, Tetracyanpropeniden und hochsubstituierten α-Aminopyridinen , 1977 .

[48]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[49]  J. Wouters,et al.  Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors. , 2011, Bioorganic & medicinal chemistry.

[50]  Andrea Mattevi,et al.  Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders , 2002, Nature Structural Biology.

[51]  W. Tatton,et al.  Antiapoptotic actions of monoamine oxidase B inhibitors. , 1998, Advances in pharmacology.

[52]  A. Maccioni,et al.  CONVENIENT SYNTHESIS OF 4-AMINO-7-(DIALKYLAMINO)PYRIDO[2,3-D]PYRIMIDINES FROM POLYSUBSTITUTED PYRIDINES , 1993 .

[53]  A. Ito,et al.  Mitochondrial targeting signal of rat liver monoamine oxidase B is located at its carboxy terminus. , 1992, Journal of biochemistry.

[54]  E. Fernández‐Álvarez,et al.  Acetylenic and allenic derivatives of 2-(5-benzyloxyindolyl) and 2-(5-hydroxyindolyl)methylamines: synthesis and in vitro evaluation as monoamine oxidase inhibitors , 1991 .

[55]  H. Tieckelmann,et al.  Reactions of Ethoxymethylenemalononitrile with Thioureas1 , 1961 .